1. Home
  2. CRBU vs MSLE Comparison

CRBU vs MSLE Comparison

Compare CRBU & MSLE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Caribou Biosciences Inc.

CRBU

Caribou Biosciences Inc.

N/A

Current Price

$0.44

Market Cap

138.3M

Sector

Health Care

ML Signal

N/A

Logo Satellos Bioscience Inc. Common Stock

MSLE

Satellos Bioscience Inc. Common Stock

N/A

Current Price

$6.65

Market Cap

144.6M

Sector

N/A

ML Signal

N/A

Company Overview

Basic Information
Metric
CRBU
MSLE
Founded
2011
2018
Country
United States
Canada
Employees
N/A
N/A
Industry
Medicinal Chemicals and Botanical Products
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
138.3M
144.6M
IPO Year
2021
2007

Fundamental Metrics

Financial Performance
Metric
CRBU
MSLE
Price
$0.44
$6.65
Analyst Decision
Buy
Strong Buy
Analyst Count
6
9
Target Price
$5.75
★ $24.17
AVG Volume (30 Days)
★ 5.3M
43.7K
Earning Date
11-16-2026
11-15-2026
Dividend Yield
N/A
N/A
EPS Growth
★ 3.64
N/A
EPS
N/A
★ N/A
Revenue
N/A
N/A
Revenue This Year
$145.34
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
★ N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.41
$5.44
52 Week High
$2.49
$13.39

Technical Indicators

Market Signals
Indicator
CRBU
MSLE
Relative Strength Index (RSI) 25.23 40.29
Support Level N/A $6.60
Resistance Level $0.58 $10.58
Average True Range (ATR) 0.04 0.51
MACD 0.02 0.08
Stochastic Oscillator 17.99 45.16

Price Performance

Historical Comparison
CRBU
MSLE

About CRBU Caribou Biosciences Inc.

Caribou Biosciences Inc is a clinical-stage Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) genome-editing biopharmaceutical company dedicated to developing transformative therapies for patients with devastating diseases. The company is focused on advancing two clinical-stage allogeneic CAR-T cell therapy product candidates for the treatment of patients with hematologic malignancies: Vispacabtagene regedleucel and CB-011. It operates in one reportable segment, which is the business of developing allogeneic CAR-T cell therapies. Geographically, it operates in the United States and the rest of the World, of which the United States derives the maximum revenue.

About MSLE Satellos Bioscience Inc. Common Stock

Satellos Bioscience Inc is a Canadian biotechnology and drug development company. The company is developing novel therapeutics that stimulate or restore muscle regeneration in severe disorders. The company's program is focused on developing an oral therapeutic drug for Duchenne muscular dystrophy that serves to correct this dysregulation, which Satellos has identified as a root cause of the progressive nature of this disease.

Share on Social Networks: